- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07457242
Recherche sur les Probiotiques : Intervention Fonctionnelle en Ouvert et Évaluation Longitudinale chez des Adultes en Bonne Santé (PROFILE)
Recherche sur les probiotiques : Intervention fonctionnelle en ouvert et évaluation longitudinale chez des adultes en bonne santé
This study is a pre-post, open-label cohort study designed to investigate how a food-grade probiotic supplement affects biological measurements and wellbeing in healthy adults. Participants will take one capsule daily for either 1 month or 6 months.
During the study, participants will complete online cognitive tasks and provide blood and stool samples collected during home visits by trained staff. The samples will be analysed to explore changes in gut bacteria and other biological markers.
This study aims to understand whether the supplement is well tolerated and whether measurable biological changes occur. The study does not involve any experimental drugs or invasive procedures beyond blood sampling and stool collection, and participants will not be asked to change any current prescribed medications or treatments; with eligibility exclusions applying for recent antibiotics or immunosuppressants. The supplement is being studied for research purposes only and is not intended to diagnose, treat, or prevent disease. Participants will be invited to participate in a follow-up visit to assess long-term effects.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Research Team
- Numéro de téléphone: +44 7757 056785
- E-mail: team@healthspanbiotics.com
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Aged 18 years or older at the time of providing informed consent.
- In generally good health, with no known medical conditions that could interfere with the aims of the study or participant safety, as judged by self-report and screening questionnaire.
- No history of significant psychiatric or neurological illness
- Ability to complete study specific tasks, including:
- Daily oral intake of a probiotic capsule
- Self-collection of stool samples
- Completion of online questionnaires and simple cognitive tasks
- Able to read, understand, and communicate in English, in order to give informed consent and follow study instructions.
- Access to the internet and a suitable device (e.g., smartphone, tablet, or computer) for completing online aspects of the study.
Exclusion Criteria:
- Participants will be excluded from the study if any of the following criteria apply:
- Use of any systemic antibiotic or systemic immunosuppressive medication within the past 8 weeks, including but not limited to:
- β-lactam antibiotics, macrolides, tetracyclines, fluoroquinolones, aminoglycosides, glycopeptides, sulfonamides, antimycobacterial agents, systemic antifungals or antivirals
- Use of any systemic immunosuppressants within the past 16 weeks, including, but not limited to:
- Systemic corticosteroids, conventional immunosuppressants, biologic immunomodulators, targeted synthetic immunosuppressants, cytotoxic chemotherapy, or transplant-related immunosuppression.
- A longer exclusion window is applied for systemic immunosuppressive therapies due to their prolonged and potentially lasting effects on immune function and gut microbial composition compared with systemic antibiotics.
- Participants who commence systemic antibiotics or immunosuppressive therapy after enrolment will not be withdrawn from safety monitoring but will stop the supplement and will not continue the intervention phase of the study. With participant consent, data collected may still be used.
- Major gastrointestinal disease or surgery:
- Any history of significant gastrointestinal disease or surgery that may alter gut microbiome composition, immune function, or nutrient absorption, including but not limited to inflammatory bowel disease (Crohn's disease, ulcerative colitis, indeterminate colitis); coeliac disease or other chronic malabsorptive disorders; chronic liver, biliary, or pancreatic disease; moderate-to-severe or unstable irritable bowel syndrome; gastrointestinal malignancy; chronic gastrointestinal motility disorders; recurrent Clostridioides difficile infection; or any major gastrointestinal surgery such as bowel resection, bariatric surgery, colectomy, ileostomy or colostomy. Prior appendectomy or cholecystectomy alone is not exclusionary.
- Current pregnancy or development of pregnancy, breastfeeding
- Known allergy to probiotic or compounding ingredients:
- Vitamin D3
- Isomaltooligosaccharide
- Yeast extract
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Short Phase Group
This group will receive supplementation for 1 month |
This probiotic is a proprietary food-grade supplement that is not yet commercially available or CE-marked. |
|
Expérimental: Long Phase Group
This group will receive supplementation for 6 months |
This probiotic is a proprietary food-grade supplement that is not yet commercially available or CE-marked. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Changes in metagenome of stool samples
Délai: From enrolment to the end of treatment at 4 or 24 weeks respectively. Optionally, a follow-up measure may be offered 24 weeks after the end of treatment.
|
The investigators will evaluate changes in genetic material in participant stool, representing establishment of the probiotic in the digestive tract |
From enrolment to the end of treatment at 4 or 24 weeks respectively. Optionally, a follow-up measure may be offered 24 weeks after the end of treatment.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in blood multiome
Délai: From enrolment to the end of treatment at 4 or 24 weeks respectively. Optionally, a follow-up measure may be offered 24 weeks after the end of treatment.
|
This measure will evaluate change in blood proteins (plasma proteome) and blood metabolites (plasma metabolome). Both measures are quantified using mass to charge ratio. |
From enrolment to the end of treatment at 4 or 24 weeks respectively. Optionally, a follow-up measure may be offered 24 weeks after the end of treatment.
|
|
Changes in cognition
Délai: Assessed weekly from enrolment and to end of treatment at 4 or 24 weeks respectively.
|
Participants will complete a weekly online cognitive test administered via our remote platform. This generates a score relativised to each participant's performance, and does not utilise a scale. |
Assessed weekly from enrolment and to end of treatment at 4 or 24 weeks respectively.
|
|
Change in daytime sleepiness
Délai: Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.
|
Participants will complete the Epworth Sleepiness Scale (ESS), with a minimum score of 0, and a maximum score of 24. A higher score indicates worse daytime sleepiness. |
Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.
|
|
Change in sleep quality
Délai: Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.
|
Participants will complete the Pittsburgh Sleep Quality Index (PSQI) survey. This has a minimum global score of 0, and a maximum of 21. A higher score indicates worse sleep quality. |
Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.
|
|
Change in self-reported wellbeing and mood
Délai: Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.
|
Participants will fill out a questionnaire at the beginning and end of the study which will ask questions about subjective mood and wellbeing. |
Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.
|
|
Adverse event monitoring
Délai: Assessed from enrolment until end of treatment at 4 or 24 weeks respectively.
|
Participants will be expected to self-report any adverse features resulting from use of the supplement |
Assessed from enrolment until end of treatment at 4 or 24 weeks respectively.
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- PROFILE
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
All personal data collected during the study will be pseudonymised at the earliest possible stage. Each participant will be assigned a unique study ID number, which will be used on all samples, questionnaires, and datasets. A separate, password-protected file will securely store the link between participant names and study IDs. This file will be accessible only to authorised study personnel.
No identifiable personal information will be included in the research database or shared with external analysts. All electronic data will be stored on secure, encrypted servers in compliance with UK GDPR and the Data Protection Act 2018. Access will be limited to members of the research team through password-protected accounts and role-based permissions.
Hard copies of personal data will not be collected or stored. Any correspondence containing identifiable information (e.g. email addresses) will be deleted or anonymised once no longer needed.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .